This pivotal phase II trial evaluated satri-cel against treatment of physician’s choice (TPC) as third-line treatment in advanced GC/GEJC with CLDN18.2 positivity (defined as ≥2+ in ≥40% tumor cells on IHC) [90]. Here, CLDN18 is linked to neoplasm.